NBIX - Neurocrine Biosciences unveils data on long-term use of Ingrezza for tardive dyskinesia

• New data from Neurocrine Biosciences ( NASDAQ: NBIX ) found that improvements were seen over 48 weeks with the use of Ingrezza (valbenazine) for tardive dyskinesia.
• Results from the KINECT 3-extension and KINECT 4 studies indicated that at 48 weeks, more than 80% of participants 65 and older met the greater than 50% improvement in the Abnormal Involuntary Movement Scale (AIMS) response threshold.
• Response thresholds were defined as "much improved" or "very much improved."
• A data analysis found that in both the 65 and older and 55 and older age groups, mean improvements in AIMS total score increased over time. At week 8 and week 48, mean score changes from baseline in the ?65 years age group were -4.5 and -8.8, respectively.
• The data will be presented at the American Association for Geriatric Psychiatry 2023 Annual Meeting that begins Friday.
• Read why Seeking Alpha contributor Sean Daly calls Neurocrine ( NBIX ) a buy.

For further details see: